Long-term Antiplatelet Therapy After Coronary Artery Bypass Grafting: Time to Reconsider Clopidogrel as the Default Monotherapy
Korean Circulation Journal · 2027 · 57
DOI: 10.4070/kcj.2026.0271 ↗Kurz gefasst
Editorial in der Zeitschrift Korean Circulation Journal, 2027. Verfasst von Jinhwan Jo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Heart and Brain Hospital, Chung-Ang University Medical Center, Gwangmyeong, Korea. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chung-Ang University, Sinai Center for Thrombosis Research and Drug Development.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Heart and Brain Hospital, Chung-Ang University Medical Center, Gwangmyeong, Korea.
- Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
- Department of Thoracic and Cardiovascular Surgery, Chung-Ang University College of Medicine, Seoul, Korea.
- CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Korea. goodoctor@naver.com.
ORCID-Profile: Jinhwan Jo, Woosik Han, Young-Hoon Jeong
Förderung
- Chung-Ang University
- Sinai Center for Thrombosis Research and Drug Development
Zitieren
APA
Jo, J., Han, W., & Jeong, Y. H. (2027). Long-term Antiplatelet Therapy After Coronary Artery Bypass Grafting: Time to Reconsider Clopidogrel as the Default Monotherapy. Korean Circulation Journal, 57. https://doi.org/10.4070/kcj.2026.0271
Vancouver
Jo J, Han W, Jeong YH. Long-term Antiplatelet Therapy After Coronary Artery Bypass Grafting: Time to Reconsider Clopidogrel as the Default Monotherapy. Korean Circulation Journal. 2027;57. doi:10.4070/kcj.2026.0271
BibTeX
@article{Jo2027,
author = {Jo, Jinhwan and Han, Woosik and Jeong, Young-Hoon},
title = {Long-term Antiplatelet Therapy After Coronary Artery Bypass Grafting: Time to Reconsider Clopidogrel as the Default Monotherapy},
journal = {Korean Circulation Journal},
year = {2027},
volume = {57},
doi = {10.4070/kcj.2026.0271}
}
EUVIMED